How deals acquire a life of their own
The synergy number was often set before diligence started: it was needed to justify the price that won the process, and diligence has since been aggregated around confirming it. Every week of process adds sunk cost, in fees and in the internal standing of the deal team, so the threshold of bad news required to stop keeps rising. Meanwhile the target has been performing for the buyer for months: the pipeline is groomed, discretionary spend is deferred, and the departing risks have been coached. Recognising these dynamics does not kill good deals. It restores the possibility of killing bad ones, which late-stage processes are otherwise structurally unable to do.
What diligence, as usually scoped, does not cover
Financial and legal diligence answer whether the numbers are real and the liabilities are disclosed. They do not answer the questions that determine whether the deal creates value: whether the fifteen people who actually constitute the capability you are buying will stay past their retention cliff, whether the customer relationships survive the founder's exit, whether the target's systems can be integrated for anything like the estimate, and whether the two organisations' ways of operating are compatible enough to merge without losing what made the target worth buying. These are operational questions, and operational diligence is the workstream most often trimmed when timelines compress.
The uncomfortable checklist before signing
- Which specific synergy lines survive if the top three customers reduce spend post-close, and what does the deal look like at half the synergy number?
- Who will run the combined entity from day one, is it agreed and communicated, and what happens to the deal logic if that person leaves within a year?
- What has the target deferred, groomed or window-dressed during the process, and what would we find in the first hundred days that diligence could not see?
- How is our own base business performing while the leadership team spends its attention on this deal, and who is checking?
- What is the walk-away price, agreed before the final negotiation round, and who in the room has the standing to enforce it?
- If this deal were brought to us today by a different team at the same price, would we start it?
Integration is the deal. Price is just the entry fee.
The valuation debate absorbs the board's attention, but the spread of outcomes on integration is wider than the spread of plausible prices. Pressure-test the integration plan as if it were the investment case, because it is: named integration leadership with real authority, not a steering committee of part-timers; a day-one plan for the decisions that cannot wait, especially reporting lines and pay; an honest map of which systems merge, which run in parallel and for how long; and retention structures for the people whose departure would void the thesis, designed around what those people actually want, which is rarely just money. A deal team that cannot produce this plan in credible detail is asking the board to approve a price without a product.
What operators who have integrated companies see in a deal book
Executives who have bought, sold and merged businesses read a deal book for what is absent. They notice when the cost synergies are specific but the revenue synergies are a percentage. They notice when the culture section is one slide of values-language and the org chart shows two heads for every function past month six. They notice when the earn-out design guarantees a dispute, because the seller controls the levers the earn-out measures. Independent perspectives at the pre-signing stage rarely change the price. What they change is the conditions, the retention design and occasionally the answer, and they give the one or two doubting board members something concrete to point at instead of an instinct they cannot defend in the room.
